NCT00765115View on ClinicalTrials.gov

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Alzheimer Disease

Interventions

DRUG

LY450139

DRUG

placebo

Trial Locations (1)

63130

For additional information regarding investigtive sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St Louis

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00765115 - A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response. | Biotech Hunter | Biotech Hunter